To determine intratumor genetic heterogeneity in uveal melanoma (UM) by multiplex ligation-dependent probe amplification (MLPA) in formalin-fixed, paraffin-embedded (FFPE) tumor tissues. METHODS. DNA was extracted from whole tumor sections and from two to nine different areas microdissected from 32 FFPE UMs. Thirty-one loci on chromosomes 1, 3, 6, and 8 were tested with MLPA for copy number changes. The tumor was considered heterogeneous at a locus if (1) the difference in dosage quotients (DQs) of any two areas was 0.2 or more, and (2) the DQs of the areas belonged to different ranges.
I n almost 50% of all patients with uveal melanoma (UM), metastatic disease develops that usually involves the liver and is almost inevitably fatal. 1 Such metastatic disease occurs almost exclusively in patients with tumors that show partial or complete deletion of chromosome 3. [2] [3] [4] Tumor dimensions at the time of initial ocular treatment and mitotic count give an indication of the likely survival time in the presence of monosomy 3. 5 Epithelioid melanoma cells, closed connective tissue loops, and a high mitotic count also suggest that a biopsy result indicating disomy 3 may be erroneous. 2,6 -12 We have developed online tools for performing multivariate analyses of UM, to estimate, with a reasonable degree of reliability, the survival probability of individual patients. 13 Such personalized prognostication enables reassurance of UM patients with good prognoses while indicating more intensive care for those having a high risk of metastasis. Genetic typing of UMs should also facilitate studies of systemic adjuvant therapy by excluding patients with a low risk of metastasis.
We and others have been typing UMs by using a variety of methods, such as cytogenetics and gene expression profiling. 14 For several years, we relied on fluorescence in situ hybridization (FISH), but this method required larger, fresh tumor samples and tested only one centromeric locus on chromosome 3, so that partial deletions were missed. 15 In late 2006, we replaced FISH with multiplex ligation-dependent probe amplification (MLPA), 16 which simultaneously tests 31 genomic sequences on chromosomes 1, 3, 6, and 8, requiring smaller tumor samples that can be either fresh or formalin-fixed and paraffin-embedded (FFPE). 17 In 2009, we validated this method in 73 UMs from patients treated between 1998 and 2000. 18 This evaluation showed that equivocal (borderline) MLPA results for chromosome 3 loci indicate a high risk of metastasis, suggesting that this phenomenon could occur as a result of melanoma cell heterogeneity, with disomy 3 cells diluting monosomy 3 cell clones.
Several research groups have reported on histologic and genetic intratumoral heterogeneity of UM. 19 -22 Such heterogeneity gives rise to a risk of sampling error when performing microbiopsy. In these studies of genetic heterogeneity of UM, only chromosome 3 was tested, 19 -22 and usually only one locus on this chromosome was assessed. We thought it would be useful to study multiple loci, not only on chromosome 3 but also on chromosomes 1, 6, and 8, which are known to develop abnormalities of prognostic significance.
The goals of this study, therefore, were to gain more knowledge on intratumoral heterogeneity in UM by assessing copy number variations within different areas of UM using MLPA on FFPE tumor tissue. If we could confirm such heterogeneity, we then proceeded to attempt to determine whether there was an association between the heterogeneous loci and equivocal results of the same loci detected in the whole tumor sections (i.e., a dilution effect). We hope that our findings will facilitate the interpretation of UM microbiopsy results of these tumors.
METHODS

Patients
The present study was performed on archival UM tissue originating from 38 patients who underwent enucleation at the Liverpool Ocular Oncology Centre (LOOC) in 2007 and 2008. None of these patients underwent eye-saving treatment (e.g., radiotherapy) before enucleation. Selected UMs were large enough to allow sampling of several distinct areas, each measuring 0.6 mm in diameter for genetic analysis (i.e., a basal diameter exceeding 11.9 mm and a thickness exceeding 5 mm). Informed consent was obtained, and the study was conducted in accordance with the Declaration of Helsinki and with institutional review board approval.
Histomorphologic Assessment
Four-micrometer sections were cut from each FFPE UM block and stained with hematoxylin and eosin (H&E) and periodic acid-Schiff (PAS), with and without hematoxylin counterstain. Histopathologic examination was performed as described elsewhere 15 for assessment of cell type 2 ; presence of PAS ϩ closed connective tissue loops; degree of pigmentation; mitotic count (number of mitoses per 40 high-power fields; one HPF ϭ 40ϫ objective); and the presence of admixed reactive cells (macrophages and/or lymphocytes). Degrees of reactive inflammation and pigmentation were graded as follows: none, 0; mild, 1; moderate, 2; and strong/numerous, 3 ( Fig. 1 ). This assessment was performed for the whole tumor as well as for each of the microdissected areas (described later). The H&E section was also used to guide microdissection for DNA extraction.
Sampling of FFPE Tissue and DNA Extraction
For DNA extraction, 20-m-thick whole tumor sections were cut, and two to nine tumor areas were either microdissected using a scalpel or a 0.6-mm-diameter donor punch (manual arrayer; Beecher Instruments, Sun Prairie, WI 
DNA Quantification and Quality Assessment
The DNA concentration and absorbance were measured with a spectrophotometer (NanoDrop; Thermo Scientific, Wilmington, DE) at 280 and 260 nm. Multiplex PCR was adapted from van Dongen et al., 23 using the RAG1, PLZF, AF4 exon 3, and AF4 exon 11 primers (Eurofins MWG Operon, London, UK), and was performed on samples with a concentration exceeding 40 ng/L, to assess DNA quality with a thermal cycler (model TC-412; Techne, Staffordshire, UK). The reaction volume was 25 L and contained 100 ng of DNA and 1ϫ highperformance buffer; 2 mM MgCl 2 ; 0.8 mM dNTP mix; 0.625 units of polymerase (ThermoStart; ABgene-Thermo Fisher Scientific); 0.5% BSA (Sigma-Aldrich Co., Ltd.); 0.1 M forward and reverse primers for RAG1, PLZF, and AF4 exon 11; and 0.2 M forward and reverse primers for AF4 exon 3. PCR products were visualized on 2% agarose gels (150 mA for 30 minutes) stained with 1ϫ SYBR DNA gel stain (SYBR Safe; Invitrogen, Paisley, UK), with a gel-imaging system (Bio Doc-It; Ultra-Violet Products, Ltd., Cambridge, UK).
MLPA Procedure and Sequencing
The MLPA procedure and sequencing were performed in 32 tumors, as previously reported 14 (Salsa P027.B1 Uveal Melanoma kit; MRC-Holland, Amsterdam, The Netherlands). In brief, six nontumor control samples were used in each MLPA assay, with 200 ng of DNA being analyzed for both tumor and nontumor samples. MLPA reactions were performed on a thermal cycler (G-Storm GS1; Gene Technologies Ltd, Essex, UK) with fragment detection being performed on a genetic analyzer (ABI-3130XL and GeneMapper software; Applied Biosystems [ABI], Foster City, CA). Raw data were received as peak heights, as a measure of peak intensity for each of the 43 probes (31 test probes and 12 control probes). MLPA was performed in triplicate for each UM sample.
MLPA Data Analysis
Analysis was performed using an adapted version of a spreadsheet (Excel; Microsoft, Redmond, WA) designed by the National Genetics Reference Laboratory (NGRL), Manchester, UK (http:/www. ngrl.org.uk/Manchester/), as described previously. 18 We modified this method to exclude UM control loci that seemed abnormal. Such abnormality was confirmed by manual analysis: abnormal probes (a dosage quotient [DQ] outside the 0.85-1.15 range) that were not detected by the program were excluded, and those falsely excluded were retrieved. The MLPA data were considered reliable if the number of control probes within the normal range was Ն7. The DQ was categorized as suggested by the NGRL as a deletion (D), Յ0.65; equivocal deletion (E), 0.65-0.84; normalϭdiploid (N), 0.85-1.14; equivocal amplification (Q), 1.15-1.35; and amplification (A) Ն1.35. 
Establishment by MLPA of the Criteria for Heterogeneity
Samples taken from each UM were assessed for heterogeneity at each locus by calculating a difference between the maximum and minimum values of DQs for a locus. This method identified the tumor samples that showed the greatest intratumoral difference at each locus. Therefore, calculation of all the differences of all sample combinations was unnecessary. DQ heterogeneity was significant if the difference between two loci was Ն0.2. This value was the difference between the upper and lower limits of the ranges for deletion, equivocal deletion, equivocal amplification, and amplification. The difference between the upper and lower limit of the diploid range was 0.3. Consequently, a second condition for the definition of a heterogeneous locus was that the DQ difference of 0.2 or more had to belong to different DQ ranges.
Correlation between Genetic and Histologic Heterogeneity
Chromosomal and histologic heterogeneity findings were coded 0 for no heterogeneity and 1 for heterogeneity. Fisher's exact test was used to correlate chromosomal heterogeneity with histologic heterogeneity with respect to cell type, closed connective tissue loops, degree of pigmentation, and reactive inflammation (SPSS ver. 16.0; SPSS, Chicago, IL).
Correlation of DQ Heterogeneity with MLPA Result from Whole Tumor Sections
To determine whether equivocal MLPA results obtained from whole UM sections could be explained by intratumoral variation in copy number, we scored the DQs obtained from the whole tumor sections as follows: 1, for equivocal loss or gain; and 0, for unequivocal outcome (i.e., normalϭdiploid and amplification or deletion). For the microdissected tumor area, we used the binary coding specified earlier. The 2 test was used to test for any association after dichotomization of the cohort for heterogeneity and equivocality.
RESULTS
Patients and Samples
A total of 160 samples from 32 UMs were studied after 27 samples from 6 tumors were excluded because of inadequate DNA quality or poor MLPA reproducibility. The 32 UMs included in the study were from 15 men and 17 women who had a mean age of 67 years (range, 41-94). (Table  1) . Two tumors showed partial loss of chromosome 3, and 
Intratumoral Chromosomal Heterogeneity
According to the criteria for the study, genetic heterogeneity was detected in 24 (75%) of the 32 UMs in between 1 and 26 of the tested 31 loci across chromosomes 1, 3, 6, and 8 (Fig. 2) . The percentage of loci that were heterogeneous varied among the UMs (Fig. 3) .
The most heterogeneous loci, in decreasing frequency, were CDKN1A (6p21.2) in 11 (35%) of 31 (95% confidence interval [CI], 19%-52%); RP1 (8q11.23) in 11 (34%) of 32 (95% CI, 18%-51%); and ROBO1 (3p12.2) in 10 (31%) of 32 (95% CI, 15%-47%) of tumors. (Fig. 4) .
Eight (25%) of the evaluated 32 melanomas were homogeneous for all 31 loci tested by MLPA (Fig. 2) . Three of these were of disomy 3 type. They had a mean LBD of 16.3 mm, with a median mitotic count of 3 of 40 HPFs, and epithelioid cells in one tumor only. Five UMs showed monosomy 3, and these had a median LBD of 15.2 mm, a median mitotic count of 9 of 40 HPFs, and epithelioid cells in two tumors. There were no tumors with partial deletion of chromosome 3 in this group.
There was no significant difference in the mean LBD (t-test P ϭ 0.533), mean mitotic count (t-test P ϭ 0.54), prevalence of epithelioid cellularity (Fisher's exact test: P ϭ 0.219), and the prevalence of monosomy 3 (Fisher's exact test: P ϭ 1.00), when homogeneous and heterogeneous UMs were compared.
Heterogeneity of Chromosome 3
Fifteen (47%) of the examined 32 UMs showed intratumoral variation of at least one locus on chromosome 3 (Fig. 2) . Of these, 13 also demonstrated heterogeneity for at least one locus on chromosomes 1, 6, and/or 8. The most common heterogeneous loci on chromosome 3 were ROBO1 (3p12.2), VHL (3p25.3), and FANCD2 (3p25.3), which occurred in 31% (95%, CI 15%-47%), 28% (95% CI, 0.16%-44%), and 22% (95% CI, 14%-36%) of all tumors, respectively (Fig. 2) .
In 11 (73%) of the 15 UMs with heterogeneity of chromosome 3, the variation involved one to six scattered loci (i.e., they were not clustered in similar chromosomal regions). In the remaining four UMs, Ͼ11 of the 13 tested loci on chromosome 3 showed heterogeneity (Fig. 2) . When UMs heterogeneous for chromosome 3 loci were compared with those tumors with homogeneous chromosome 3 loci, there was no significant difference between the mean LBD, the mean mitotic rate, the presence of epithelioid cells, and the presence of partial or total chromosome 3 loss for any of the chromosome 3 loci (Table 2) .
Of note, three of the four UMs with chromosome 3 heterogeneity of Ն11 loci showed gain of one or both arms of chromosome 3 in at least one part of the tumor (Fig. 5) . Of the remaining 17 UMs that were homogenous for all 13 loci on chromosome 3, 5 were of the disomy 3 type, whereas 12 showed monosomy 3 and none showed partial chromosome 3 loss.
Correlation between Genetic and Histomorphologic Heterogeneity
Intratumoral histomorphologic heterogeneity for melanoma cell type was detected in 10 of 32 UMs. Such cellular heterogeneity correlated with intratumoral heterogeneity of VHL (3p25.3), CDKN1A, and RP1 (Table 3) , as well as heterogeneity of connective tissue loops (P ϭ 0.001). Heterogeneity of the latter also correlated with an intratumoral copy number difference in CDKN1A. There was no correlation between genetic heterogeneity and variation in reactive inflammation or tumor pigmentation ( Table 3) .
Distribution of Chromosomal Changes across Uveal Melanomas Not Showing Heterogeneity at a Particular Locus
The most common abnormalities in our cohort of UMs were deletions of chromosome 3 and gains of the long arm of chromosome 8. Loss of loci located on chromosome 3 was present in between 25% (for VHL, 3p25.3) and 58% (for FHIT(ii), 3p14.2) of the UMs. Gains of loci on 8q were present in between 41% (for RP1, 8q11.23) and 66% (DDEF1, 8q24.2) of the tumors. Depending on which locus was considered, amplifications on 6p occurred in 19% to 26% of the UMs. Deletions of loci were seen in 13% to 28% and 19% of the tumors on 1p and 6q, respectively. Duplications on 1p, 3, and 6q and deletions on 6p were rare (Fig. 6 ).
Correlation between Genetic Heterogeneity and Equivocal MLPA Results
Equivocal results obtained from the whole tumor sections correlated with the underlying intratumoral copy number differences ( 2 test, P ϭ 0.001).
DISCUSSION
The main finding of our investigation using MLPA on FFPE material is that 75% of the analyzed UMs showed intratumoral heterogeneity of chromosomes 1, 3, 6, or 8. Almost 50% of tumors showed intratumoral heterogeneity of at least one locus of chromosome 3. The loci showing heterogeneity most commonly were ROBO1, CDKN1A, and RP1. Most of the UMs showing heterogeneity of chromosome 3 also showed heterogeneity of loci on the other examined chromosomes. Intratumoral heterogeneity of some loci correlated with variation in cell type but not with reactive inflammation or degree of pigmentation. Genetic heterogeneity correlated with equivocal MLPA results obtained from whole tumor sections. To our knowledge, no studies have been undertaken to investigate the intratumoral heterogeneity of multiple gene loci in UM. In this cohort of UMs, 24 (75%) of 32 tumors showed intratumoral heterogeneity of 1 to 26 loci across chromosomes 1, 3, 6, and 8. Only one quarter of the studied UMs were homogeneous for all 31 loci tested by MLPA. Small tumors (LBD Ͻ11.9 mm; thickness Ͼ5 mm) were excluded from the study because it was not possible to sample multiple sites from such cases. We plan, however, to examine increasingly smaller UMs and to compare the MLPA results with those in the present study.
The degree of genetic heterogeneity varied between the examined UMs (Fig. 3) . Slight variation involving up to six scattered loci was seen in seven UMs, whereas five tumors showed heterogeneity of Ͼ40% of loci on at least three of the four chromosomes examined. The heterogeneity of single isolated loci should be interpreted with caution, as these differences could be an artifact, as a result of DNA degradation after formalin fixation. However, copy number differences involving several loci across a large chromosomal area are associated with true heterogeneity between these regions.
The most heterogeneous loci detected using MLPA in decreasing frequency were CDKN1A (35% of UMs), RP1 (34%), and ROBO1 (31%). The least heterogeneous locus was MYCBP, showing a copy number variation in only three tumors. Because of the short follow-up period and the small number of patients with metastatic disease, the clinical relevance of these findings has yet to be determined.
With respect to chromosome 3 only, approximately half of the examined UMs showed heterogeneity of at least one locus, with 11 of the tumors demonstrating copy number variation in up to 6 loci. When compared with baseline MLPA data used for classifying the UM for chromosome 3 status, this heterogeneity in the loci between areas did not result in a change in interpretation (Table 1) . Four of these UMs, however, showed marked heterogeneity involving Ն11 of the 13 loci examined on chromosome 3. The intratumoral heterogeneity in these four UMs was enough to result in contradictory interpretation of the chromosomal status in different parts of the same tumor (Table 1) . For example, one microdissected area of the UMs indicated monosomy 3, and another area showed amplification of several loci on chromosome 3 (Figs. 5F-J).
Other groups have reported chromosome 3 heterogeneity in 6.6% 20 to 14% 21 of tumors; however, they applied only one chromosome 3 probe, using FISH or chromogenic (C)ISH, and so the prevalence of this phenomenon is probably underreported. The advantage of MLPA over these cytogenetic methods is that it allows for the simultaneous examination of 13 chromosome 3 loci. Some researchers have suggested that chromosome 3 abnormalities are more common at the tumor base 22 and are associated with melanoma cell type 19 and presence of PAS ϩ connective tissue loops. 21 In the present study, we demonstrated a strong correlation between genetic heterogeneity of some chromosomal loci and differences in cell type, as well as the presence or absence of PAS ϩ connective tissue loops. Because the copy number variation affected numerous different loci on chromosome 3 and the number of UMs examined in this cohort was relatively small, the statistical analysis for a potential association between the geographic location of a microdissected sample (i.e., apex versus base or anterior versus posterior) and copy number variation was not possible.
An interesting finding was that genetic heterogeneity of chromosomes 1, 3, 6, and 8 did not correlate with intratumoral variation in reactive inflammation. This result suggests that the copy number variation observed using MLPA was most likely to be caused by the presence of melanoma cell clones differing in chromosome 3 copy number. This impression is supported by our finding that equivocal MLPA data from whole tumor sec- P-values were obtained from the Fisher's exact test and the t-test. There was no significant difference between the mean LBD, the mean mitotic rate, the presence of epithelioid cells, and the presence of partial or total chromosome 3 loss for any of the chromosome 3 loci.
tions were strongly associated with copy number variation in the microdissected areas (P ϭ 0.001). However, to support the hypothesis that admixed reactive cells in UMs play a minor role in producing heterogeneous MLPA data, we are currently investigating macrophage-and lymphocyte-rich UMs by using fluorescence-activated cell sorting methods to separate neoplastic from nonneoplastic cell populations.
Also of particular interest was that four of the UMs analyzed demonstrated gains on chromosome 3, which consisted of partial or total gain of one or both arms of chromosome 3. To our knowledge, this finding has not been reported. Although MLPA cannot detect polyploidy, we believe that the gains observed on chromosome 3 were aneuploid aberrations, since loss of 1p was also present in three of these UMs, and loss of 6q and 8p was found in one other UMs. Three of these four UMs showed marked intratumor heterogeneity of chromosome 3. Monosomy 3 is considered an early event in UM 24 ; therefore, UMs showing monosomy 3 in at least one area of the tumor and two or more copies of chromosome 3 in other regions of the same tumor are particularly interesting, suggesting that additional copies of chromosome 3 were gained during tumor progression.
In summary, we have demonstrated that (1) genetic heterogeneity of chromosomes 1, 3, 6, and 8 is present in most FFPE UMs, so that a single random sample may not be representative of the whole tumor, with the result that false showed two copies of 3; normal 1, and 6; and loss of 8p and gains on 8q. Areas (i) and (iii) showed gains of multiple loci on both arms of 3 and differences in the status of 1p, 6p, and 8. Area (iv) (not shown) was similar to (i). There were no significant differences in histomorphology in the areas examined. (F-J) UM H08. Area (i) showed monosomy 3 and loss of chromosome 1. Area (iii) was similar (not shown). Area (ii) showed a partial gain of 3p25.3-3p22 and two copies of 3q, a partial loss of 1p, and gains of 6p and 8q. Area (iv) (not shown) was similar to (ii). Histologically, there are differences only in the degree of pigmentation of the spindle cells.
reassurance regarding the survival prognosis is provided; (2) although genetic heterogeneity for chromosome 3 occurred in 47% of the UMs, it involved only a few scattered loci in most tumors and did not change the interpretation of chromosome 3 status between the microdissected areas; (3) UMs containing clones with gains in chromosome 3 occur and tend to show a high degree of heterogeneity; and (4) . Distribution of chromosomal abnormalities. Het, heterogeneous loci; gain, gain in copy number; eq gain, equivocal gain; normal, normal copy number; eq loss, equivocal loss; loss, loss in copy number. The null hypothesis was that there is no association between intratumoral heterogeneity of histomorphologic variables (cell type, closed connective tissue loops, pigmentation of tumor cells, and admixed reactive cells) and heterogeneity of 31 loci tested by MLPA. Bold values indicate strong evidence against the null hypothesis (i.e., an association between a variable in a column with a variable in a row). different melanoma cell clones and not by reactive cells, although further investigation using fresh tumor material is needed to confirm this impression.
